Senhwa Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer’s Talazoparib for the Treatment of Prostate Cancer

Senhwa Biosciences, Inc. announced that their first patient had been successfully dosed, in a phase I clinical study evaluating the combined treatment with Senhwa’s Pidnarulex and Pfizer’s PARP inhibitor, Talazoparib (Talzenna), in patients with metastatic castration-resistant prostate cancer.